​

• Takeda  

      An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy with Vedolizumab Intravenous (IV) and                   Adalimumab Subcutaneous (SC) or Vedolizumab IV and Ustekinumab IV/SC in Moderate to Severe Crohn’s Disease (CD)

      Study Details | A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease |      ClinicalTrials.gov

​

• Johnson & Johnson  

          A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus            Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease

​Study Details | NCT07499232 | A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease | ClinicalTrials.gov

​

​

​

​

​

​

​

​​